Meeting
2020 ASCO Virtual Scientific Program
Clinical outcomes of the combination of bevacizumab and ttfields in patients with recurrent glioblastoma: Results of a phase II clinical trial.
Authors
Jaleh Fallah
Cleveland Clinic Foundation, Cleveland, OH
Jaleh Fallah , Rekha T. Chaudhary , Lisa R. Rogers , Wei Wei , Cathy J. Brewer , David M. Peereboom , Manmeet Singh Ahluwalia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01894061
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2537)
DOI
10.1200/JCO.2020.38.15_suppl.2537
Abstract #
2537
Poster Bd #
28
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
First Author: Manmeet Singh Ahluwalia
Poster
2015 ASCO Annual Meeting
Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.
First Author: Ashley Ghiaseddin
Poster
2022 ASCO Annual Meeting
Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295.
First Author: Jian Li Campian
Poster
2022 ASCO Annual Meeting
A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma.
First Author: Masamichi Takahashi